BeiGene ranks C in the innovative drug market and will soon become a listed pharmaceutical company in the "A+H+N" three places

According to the news recently disclosed by the China Securities Regulatory Commission, BeiGene has agreed to register for the IPO of BeiGene Science and Technology Innovation Board
.
This means that BeiGene will soon be listed on the Science and Technology Innovation Board and is expected to be listed in three places at the same time
.
BeiGene is a biotechnology company focusing on research, development, production and commercialization of innovative drugs
.
In early 2021, BeiGene submitted a prospectus to the Science and Technology Innovation Board, and plans to raise 20 billion yuan
.
Among them, 13.
246 billion yuan was used for drug clinical trial research and development projects, 468 million yuan was used for research and development center construction projects; 150 million yuan was used for production base research and development and industrialization projects, 136 million yuan was used for marketing network construction projects, and 6 billion yuan was used for Supplement working capital
.
It is understood that before the IPO, BeiGene had two independent BTK small molecule inhibitors, Baiyueze (Zebutinib Capsules) and the anti-PD-1 monoclonal antibody Bezean (Tilelizumab injection).
The drug developed is in the commercialization stage
.
Among them, Baiyueze started commercial sales in the United States in November 2019, and began commercial sales in China in June 2020; Baizean started commercial sales in China in March 2020
.
In addition, this year BeiGene and Novartis also reached a licensing cooperation agreement on the development and commercialization of Baizean in North America, Europe, Japan and other countries, with a total transaction amount of more than 2.
2 billion US dollars
.
Since 2018, BeiGene has burned nearly 30 billion yuan
.
According to the prospectus, BeiGene achieved revenue of 1.
31 billion yuan, 2.
954 billion yuan, 2.
12 billion yuan, and 6.
227 billion yuan in the first three quarters of 2018, 2019, 2020, and 2021, respectively; net profit losses were 4.
748 billion yuan and 6.
928 billion yuan, respectively.
100 million yuan, 11.
4 billion yuan, 5.
5 billion yuan
.
Regarding the increase in revenue in the first three quarters of 2021 and the decrease in net loss, BeiGene said that it was mainly due to the expansion of the company’s self-developed products and the sales scale of Amgen’s authorized products, and the production of disposable technologies in the first quarter of 2021.
Authorized income
.
The company expects annual revenue in 2021 to be 6.
85 billion yuan to 8.
02 billion yuan, net loss attributable to shareholders of the parent company is 8.
542 billion yuan to 11 billion yuan, and net loss attributable to shareholders of the parent company after deducting non-recurring gains and losses is 8.
577 billion yuan Yuan to 11.
047 billion yuan
.
It is worth mentioning that BeiGene has always been Hillhouse’s "good heart".
As early as before BeiGene was listed on Nasdaq, Hillhouse and CPE Yuanfeng Capital participated in BeiGene's Series A financing
.
After that, it continued to appear in the list of financing institutions of BeiGene
.
Public information shows that in the past 10 years, BeiGene has raised more than 7.
456 billion US dollars in the primary and secondary capital markets, or about 47.
6 billion yuan
.
Among them, Hillhouse has a record of up to 8 capital injections, which shows Hillhouse's preference for biomedical companies
.
Judging from the F13 documents in the third quarter, BeiGene is the largest position among Hillhouse US stocks, holding 5,472,300 shares, corresponding to a market value of US$1.
986 billion
.
Up to now, BeiGene's share price has risen from the issue price of US$24 to US$389.
34, with a market value of US$36.
530 billion
.
In addition to Hillhouse, "Hillhouse" is also heavily stocked in BeiGene
.
Industry analysts believe that behind these large-scale institutions investing in BeiGene, they are looking at the future potential of the company
.
In recent years, Hillhouse's investment logic has hardly changed whether it is in the primary or secondary markets
.
In the primary market, it has successively invested in a number of biomedical companies such as Amador Bio, Yingmai Medical, Pengli Bio, Anjisheng Bio, Huo De Bio, Dingtai Pharmaceutical Research, etc.
In the secondary market, although part of its holdings was reduced in the third quarter pharmaceutical stocks, but still holds Hengrui medicine, Hualan, Franc Group, BGI and so on
.